Skip to content

Athira Pharma prices upsized IPO at $17

September 18, 2020

Athira Pharma (ATHA) has priced its upsised IPO of 12M (from 10M) common shares at $17.00/share, for expected gross proceeds of $204M.

Athira is a biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.

Trading commences September 18.

Underwriters’ over-allotment is an additional 1.8M shares.

Goldman Sachs, Jefferies, Stifel and JMP securities are acting as joint book-running managers.

Closing date is September 22.

The company’s lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule HGF/MET activator indicated for the treatment of Alzheimer’s disease.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: